白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌的效果及安全性研究

Effect and Safety of Albumin-bound Paclitaxel Combined with Tegafur in the Treatment of Elderly Patients with Advanced Pancreatic Cancer

目的分析白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌的临床疗效以及安全性。方法选取2016年3月—2019年2月该院收治的老年晚期胰腺癌患者共60例分为联用组和单药组,单药组应用替吉奥进行治疗,联用组联合应用白蛋白结合型紫杉醇以及替吉奥进行治疗,比较两组用药方式的临床疗效以及安全性。结果联用组的DCR为93.33%,单药组为73.33%,组间差异有统计学意义(χ^2=4.320,P=0.038<0.05);联用组的ORR为46.67%,单药组为36.67%,组间差异无统计学意义(χ^2=0.617,P=0.432>0.05);联用组的(Ⅰ+Ⅱ)度感觉神经异常发生率为53.33%,单药组为6.67%,组间差异有统计学意义(χ^2=15.556,P=0.000<0.05);同时联用组的(Ⅰ+Ⅱ)度脱发发生率为46.67%,单药组为3.33%,组间差异有统计学意义(χ^2=15.022,P=0.000<0.05)。结论白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌的临床疗效肯定,且不良反应可耐受。

Objective To analyze the clinical efficacy and safety of albumin-bound paclitaxel combined with tegafur in the treatment of elderly patients with advanced pancreatic cancer.Methods A total of 60 elderly patients with advanced pancreatic cancer admitted to our hospital from March 2016 to February 2019 were divided into a combination group and a single-agent group.The single-agent group was treated with Tiggio,and the combination group was combined with white.Protein-bound paclitaxel and tegafur were treated to compare the clinical efficacy and safety of the two groups.Results The DCR of the combination group was 93.33%,and that of the single drug group was 73.33%.There was statistical significance between the groups(χ^2=4.320,P=0.038<0.05).The ORR of the combination group was 46.67%,and the single drug group was 36.67%.There was no statistically significant difference between the groups(χ^2=0.617,P=0.432>0.05).The incidence of(I+II)sensory neuron abnormalities was 53.33%in the combination group and 6.67%in the single drug group.There was statistical significance between the groups(χ^2=15.556,P=0.000<0.05);the incidence rate of(I+II)degree hair loss was 46.67%in the combination group and 3.33%in the single drug group,and there was statistical significance between the groups(χ^2=15.022,P=0.000<0.05).Conclusion The clinical efficacy of albumin-bound paclitaxel combined with tegafur in the treatment of elderly patients with advanced pancreatic cancer is positive,and adverse reactions can be tolerated.